Costanzi, Stefano
 Distribuzione geografica
Continente #
NA - Nord America 214
EU - Europa 164
AS - Asia 57
AF - Africa 6
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 444
Nazione #
US - Stati Uniti d'America 213
SE - Svezia 53
DE - Germania 35
CN - Cina 32
FR - Francia 26
PL - Polonia 12
IN - India 10
IE - Irlanda 9
SG - Singapore 8
IT - Italia 7
UA - Ucraina 7
CI - Costa d'Avorio 6
RU - Federazione Russa 4
BE - Belgio 3
FI - Finlandia 3
TR - Turchia 3
EU - Europa 2
GB - Regno Unito 2
HK - Hong Kong 2
IR - Iran 2
NL - Olanda 2
AU - Australia 1
CA - Canada 1
NO - Norvegia 1
Totale 444
Città #
Chandler 71
Ashburn 15
New York 14
Kraków 12
Nanjing 10
Dublin 9
San Mateo 8
Ann Arbor 7
Marseille 7
Wilmington 7
Abidjan 6
Bremen 6
Jacksonville 6
Princeton 6
Boston 5
Dearborn 5
Singapore 4
Beijing 3
Brussels 3
Cattolica 3
Fairfield 3
Izmir 3
Augusta 2
Changchun 2
Helsinki 2
Hong Kong 2
Los Angeles 2
Moscow 2
Seattle 2
Shenyang 2
Woodbridge 2
Zhengzhou 2
Chicago 1
Ergolding 1
Guangzhou 1
Houston 1
Kemerovo 1
Kish 1
Lawrence 1
Mountain View 1
Munich 1
Nanchang 1
Oslo 1
Penrith 1
Redwood City 1
Rome 1
San Francisco 1
Stockholm 1
Tianjin 1
Toronto 1
Totale 251
Nome #
A SPRY2 mutation leading to MAPK/ERK pathway inhibition is associated with an autosomal dominant form of IgA nephropathy. 134
Contrast-enhanced ultrasonography in chronic glomerulonephritides: correlation with histological parameters of disease activity 63
Defective activation of the MAPK/ERK pathway, leading to PARP1 and DNMT1 dysregulation, is a common defect in IgA nephropathy and Henoch-Schönlein purpura 62
Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: A randomized controlled trial 57
Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies 49
Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies 45
Deterioration in Clinical Status Is Not Enough to Suspend Eculizumab: A Genetic Complement-Mediated Atypical Hemolytic Uremic Syndrome Case Report 42
Totale 452
Categoria #
all - tutte 1.999
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.999


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202036 0 4 1 4 1 2 6 0 6 2 9 1
2020/202116 0 2 0 1 1 0 5 0 2 1 2 2
2021/202268 6 1 3 1 5 2 0 13 4 4 13 16
2022/2023181 26 22 12 34 7 26 15 13 19 0 5 2
2023/202462 3 14 1 7 0 8 6 1 0 4 9 9
2024/20252 1 1 0 0 0 0 0 0 0 0 0 0
Totale 452